Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
October 21, 2022 at 09:32 am
Share
Evolutionary Genomics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 0.545277 million compared to USD 1.06 million a year ago. Basic loss per share from continuing operations was USD 0.09 compared to USD 0.19 a year ago. Diluted loss per share from continuing operations was USD 0.09 compared to USD 0.19 a year ago.
For the nine months, net loss was USD 1.6 million compared to USD 2.13 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.4 a year ago. Diluted loss per share from continuing operations was USD 0.29 compared to USD 0.4 a year ago.
Evolutionary Genomics, Inc. is a genomics research and development company. The Company is focused on the identification and validation of genes that impact commercially traits in crops for the agriculture industry. It uses the Adapted Traits Platform (ATP) to identify commercially valuable genes that control important traits in animals and plants. Its platform identifies genes that have changed successfully to impart new or improved traits. The Company has applied its ATP in research projects, including identifying genes responsible for increases in yield in corn, increases in yield in rice, drought tolerance and sugar content in tomatoes and pest/disease resistance in soybeans, cassava, beans, tomatoes, and cotton. The Company uses ATP to perform throughput molecular evolution analysis to identify positively selected genes based on non-synonymous site (Ka) and synonymous site (Ks) analysis.